CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...